Toppublicaties

Mammacarcinoom

Geselecteerd door: Mammacarcinoom
  • juni 2023

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

  • Turner N C, Oliveira M, Howell S J, et al.
  • mei 2023

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

  • AndrĂ© F, Hee Park Y, Kim SB, et al.
  • april 2023

Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial

  • Meduri B, Baldissera A, Iotti C, et al.
  • maart 2023

Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trial

  • Tjan-Heijnen VCG, Lammers SWM, Geurts SME, et al.
  • maart 2023

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

  • Pala L, De Pas T, Pagan E, et al.
  • maart 2023

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

  • Tolaney SM, Tarantino P, Graham N, et al.
  • februari 2023

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients' Needs?

  • Jongbloed EM, Blommestein HM, van Schoubroeck HM, et al.
  • februari 2023

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review

  • van den Ende NS, Nguyen AH, Jager A, et al.
Joan Heijns

Lagere tamoxifendosis leidt tot minder bijwerkingen
  • februari 2023

The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer

  • Buijs SM, Hoop EO, Braal CL, et al.
  • januari 2023

Approaches to Fertility Preservation for Young Women With Breast Cancer

  • Razeti MG, Soldato D, Arecco L, et al.
  • januari 2023

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry

  • Ibragimova KIE, Geurts SME, Meegdes M, et al.
  • december 2022

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

  • Nuciforo P, Townend J, Piccart MJ, et al.
Gedownload van https://medischeoncologie.nl/ op 22-09-2023 om 05:54. Copyright (C) 2023 BPM Medica.

Deel deze pagina